<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">evrazkar</journal-id><journal-title-group><journal-title xml:lang="ru">Евразийский Кардиологический Журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Eurasian heart journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-1685</issn><issn pub-type="epub">2305-0748</issn><publisher><publisher-name>Евразийская ассоциация кардиологов</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2225-1685-2022-3-90-96</article-id><article-id custom-type="elpub" pub-id-type="custom">evrazkar-6343</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Особенности течения артериальной гипертонии у пациентов с перенесённой новой коронавирусной инфекции</article-title><trans-title-group xml:lang="en"><trans-title>Features of the manifestation of arterial hypertension in patients with a new coronavirus infection</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7381-7818</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Солнцева</surname><given-names>Т. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Solnceva</surname><given-names>T. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Солнцева Татьяна Дмитриевна, аспирант отдела гипертонии</p><p>ул. 3-я Черепковская, д. 15 А, г. Москва 121552</p></bio><bio xml:lang="en"><p>Tat’yana D. Solnceva, postgraduate student</p><p>A. L. Myasnikov Research Institute of Cardiology</p><p>Department of Hypertension</p><p>121552</p><p>st. 3rd Cherepkovskaya, 15 A</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8958-3588</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лачугин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lachugin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лачугин Антон Андреевич, студент 6 курса</p><p>ул. Миклухо-Маклая, 6, г. Москва 117198</p></bio><bio xml:lang="en"><p>Anton A. Lachugin,  6th year student</p><p>117198</p><p>st. Miklukho-Maklaya 6</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0060-095X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сивакова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sivakova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сивакова Ольга Анатольевна, к.м.н., заведующая отделением артериальной гипертонии</p><p>ул. 3-я Черепковская, д. 15 А, г. Москва 121552</p></bio><bio xml:lang="en"><p>Ol’ga A. Sivakova, Candidate of Medical Sciences, Head of the Department</p><p>A. L. Myasnikov Research Institute of Cardiology</p><p>Department of Arterial Hypertension</p><p>121552</p><p>st. 3rd Cherepkovskaya, 15 A</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1576-4877</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чазова Ирина Евгеньевна, академик РАН, профессор, д.м.н., руководитель отдела гипертонии</p><p>ул. 3-я Черепковская, д. 15 А, г. Москва 121552</p></bio><bio xml:lang="en"><p>Irina E. Chazova, Academician, Professor, Doctor of Medical Sciences, Head of the Department</p><p>A. L. Myasnikov Research Institute of Cardiology</p><p>Department of Hypertension</p><p>121552</p><p>st. 3rd Cherepkovskaya, 15 A</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии им. ак. Е.И. Чазова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>RUDN University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии им. ак. Е.И. Чазова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology; Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>12</day><month>10</month><year>2022</year></pub-date><volume>0</volume><issue>3</issue><fpage>90</fpage><lpage>96</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Солнцева Т.Д., Лачугин А.А., Сивакова О.А., Чазова И.Е., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Солнцева Т.Д., Лачугин А.А., Сивакова О.А., Чазова И.Е.</copyright-holder><copyright-holder xml:lang="en">Solnceva T.D., Lachugin A.A., Sivakova O.A., Chazova I.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.heartj.asia/jour/article/view/6343">https://www.heartj.asia/jour/article/view/6343</self-uri><abstract><p>   Цель. Оценить наличие основных факторов риска, ассоциированных клинических состояний, степень поражения органов-мишеней у пациентов с артериальной гипертонией в зависимости от перенесённой новой коронавирусной инфекции.   Материалы и методы. В ретроспективное когортное исследование были включены 284 пациента с артериальной гипертонией, из которых 162 перенесли новую коронавирусную инфекцию. Пациенты, перенёсшие новую коронавирусную инфекцию, были разделены на группы в зависимости от тяжести заболевания. Критериями включения были наличие артериальной гипертонии в анамнезе и / или приём антигипертензивной терапии.   Результаты. У пациентов с гипертонией, перенёсших новую коронавирусную инфекцию, чаще встречаются такие факторы риска, как курение, избыточная масса тела, ранняя менопауза по сравнению с пациентами с АГ без указаний на перенесённую COVID-19. При сравнении пациентов с различной тяжестью новой коронавирусной инфекции повышенный уровень мочевой кислоты и гиперхолестеринемия ассоциировались с более тяжелым течением COVID-19 (p &lt; 0,05). Пациенты с наличием хронической болезни почек, цереброваскулярных болезней, значимого атеросклеротического поражения брахиоцефальных артерий, а также сахарного диабета 2 типа имели больший шанс летального исхода от новой коронавирусной инфекции (p &lt; 0,05). Достоверной разницы между сравниваемыми группами по распространённости ишемической болезни сердца, фибрилляции предсердий, хронической сердечной недостаточности, а также характеру суточного профиля АД и тяжелым течением COVID-19 получено не было.   Заключение. Наличие сахарного диабета 2 типа, хронической болезни почек, цереброваскулярных болезней, значимого атеросклеротического поражения брахиоцефальных артерий, а также гиперурикемии или гиперхолестеринемии у пациентов с АГ статистически значимо увеличивает риск тяжёлого течения новой коронавирусной инфекции.</p></abstract><trans-abstract xml:lang="en"><p>   The purpose. Assessment of the presence of the cardiovascular risk factors, associated clinical conditions, the degree of target organ damage in patients with arterial hypertension depending on the new coronavirus infection.   Material and methods. In a retrospective cohort study 284 patients with arterial hypertension were identified, 162 of them had a novel coronavirus infection and 122 patients didn’t have a history of a new coronavirus infection. Patients who had a new coronavirus infection were divided into groups depending on the disease. Inclusion criteria were the presence of arterial hypertension in history and taking antihypertensive therapy.   Results. Patients with hypertension who’ve had a new coronavirus infection are more likely to have risk factors such as smoking, overweight, early menopause as opposed to patients with hypertension without indication of past COVID-19. Comparing patients with increased severity of the novel coronavirus infection elevated uric acid levels and hypercholesterolemia were associated with more severe COVID-19 (p &lt; 0.05). Patients with chronic kidney disease, cerebrovascular disease, detection of atherosclerotic lesions of the brachiocephalic arteries and diabetes mellitus have an increased probability of deaths occur from the novel coronavirus infection (p &lt; 0.05). There was no significant difference between the compared groups of coronary heart disease, atrial fibrillation, chronic heart failure and also the daily blood pressure profile and a severe course of COVID-19.   Сonclusion. The presence of diabetes mellitus, cerebrovascular disease, chronic kidney disease, detection of atherosclerotic lesions of the brachiocephalic arteries, and also hyperuricemia or hypercholesterolemia in patients with hypertension revealed a risk of severe coronavirus infection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>новая коронавирусная инфекция</kwd><kwd>COVID-19</kwd><kwd>факторы риска</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>поражение органов-мишеней</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>coronavirus infection</kwd><kwd>COVID-19</kwd><kwd>risk factors</kwd><kwd>cardiovascular disease</kwd><kwd>target organ damage</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Финансирование статьи не осуществлялось</funding-statement><funding-statement xml:lang="en">The article was not funded</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction.BMJ 2020; 12; 368:m1036. https://doi.org/10.1136/bmj.m1036</mixed-citation><mixed-citation xml:lang="en">Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction.BMJ 2020; 12; 368:m1036. https://doi.org/10.1136/bmj.m1036</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3</mixed-citation><mixed-citation xml:lang="en">Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И. Е. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии / И. Е. Чазова, Ю. В. Жернакова // Системные гипертензии. – 2019. – 16 (1): 6-31 [Chazova I. E., Zhernakova Y. V. Diagnosis and treatment of arterial hypertension. Syst Hypertens 2019; 16: 6–31 (In Russ.)]. https://doi.org/10.26442/2075082x.2019.1.190179</mixed-citation><mixed-citation xml:lang="en">Чазова И. Е. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии / И. Е. Чазова, Ю. В. Жернакова // Системные гипертензии. – 2019. – 16 (1): 6-31 [Chazova I. E., Zhernakova Y. V. Diagnosis and treatment of arterial hypertension. Syst Hypertens 2019; 16: 6–31 (In Russ.)]. https://doi.org/10.26442/2075082x.2019.1.190179</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Varga Z., Flammer A. J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5</mixed-citation><mixed-citation xml:lang="en">Varga Z., Flammer A. J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Azra M., Nawaf Abdulaziz A., Mohammad Hamad A. et al. Hypertension phenotypes, target organ damage and stiff arteries and severity of COVID-19. Journal of Hypertension; 2021: 39-e403. https://doi.org/10.1097/01.hjh.0000749260.73954.dc</mixed-citation><mixed-citation xml:lang="en">Azra M., Nawaf Abdulaziz A., Mohammad Hamad A. et al. Hypertension phenotypes, target organ damage and stiff arteries and severity of COVID-19. Journal of Hypertension; 2021: 39-e403. https://doi.org/10.1097/01.hjh.0000749260.73954.dc</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chen B., Lu C., Gu H-Q. et al. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol (Lausanne) 2021;12: 633767. https://doi.org/10.3389/fendo.2021.633767</mixed-citation><mixed-citation xml:lang="en">Chen B., Lu C., Gu H-Q. et al. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol (Lausanne) 2021;12: 633767. https://doi.org/10.3389/fendo.2021.633767</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chauhan K., Pattharanitima P., Piani F. et al. Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19. Novel Research Findings Am J Nephrol. 2019; 53: 78-86. https://doi.org/10.1159/000520355</mixed-citation><mixed-citation xml:lang="en">Chauhan K., Pattharanitima P., Piani F. et al. Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19. Novel Research Findings Am J Nephrol. 2019; 53: 78-86. https://doi.org/10.1159/000520355</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hariyanto T. I., Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr Clin Res Rev 2020; 14: 1463–1465. https://doi.org/10.1016/j.dsx.2020.07.054</mixed-citation><mixed-citation xml:lang="en">Hariyanto T. I., Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr Clin Res Rev 2020; 14: 1463–1465. https://doi.org/10.1016/j.dsx.2020.07.054</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Aghili S. M., Ebrahimpur M., Arjmand B. et al. Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis. Int J Obes (Lond). 2021; 45 (5): 998-1016. https://doi.org/10.1038/s41366-021-00776-8</mixed-citation><mixed-citation xml:lang="en">Aghili S. M., Ebrahimpur M., Arjmand B. et al. Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis. Int J Obes (Lond). 2021; 45 (5): 998-1016. https://doi.org/10.1038/s41366-021-00776-8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Izcovich A., Ragusa M. A., Tortosa F. et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One. 2020; 17; 15 (11): e0241955. https://doi.org/10.1371/journal.pone.0241955</mixed-citation><mixed-citation xml:lang="en">Izcovich A., Ragusa M. A., Tortosa F. et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One. 2020; 17; 15 (11): e0241955. https://doi.org/10.1371/journal.pone.0241955</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Singh J., Malik P., Patel N. et al. Kidney disease and COVID-19 disease severity—systematic review and meta-analysis. Clin Exp Med 2022; 22: 125–35. https://doi.org/10.1007/s10238-021-00715-x</mixed-citation><mixed-citation xml:lang="en">Singh J., Malik P., Patel N. et al. Kidney disease and COVID-19 disease severity—systematic review and meta-analysis. Clin Exp Med 2022; 22: 125–35. https://doi.org/10.1007/s10238-021-00715-x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Vinciguerra M., Romiti S., Fattouch K. et al. Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. J Clin Med 2020; 9 (7): 2095. https://doi.org/10.3390/jcm9072095</mixed-citation><mixed-citation xml:lang="en">Vinciguerra M., Romiti S., Fattouch K. et al. Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. J Clin Med 2020; 9 (7): 2095. https://doi.org/10.3390/jcm9072095</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar A., Arora A., Sharma P. et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020; 14: 535–45. https://doi.org/10.1016/j.dsx.2020.04.044</mixed-citation><mixed-citation xml:lang="en">Kumar A., Arora A., Sharma P. et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020; 14: 535–45. https://doi.org/10.1016/j.dsx.2020.04.044</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kummer B. R., Klang E., Stein L. K. et al. History of Stroke Is Independently Associated With In-Hospital Death in Patients With COVID-19. Stroke 2020; 51: 3112–4. https://doi.org/10.1161/STROKEAHA.120.030685</mixed-citation><mixed-citation xml:lang="en">Kummer B. R., Klang E., Stein L. K. et al. History of Stroke Is Independently Associated With In-Hospital Death in Patients With COVID-19. Stroke 2020; 51: 3112–4. https://doi.org/10.1161/STROKEAHA.120.030685</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Strausz S., Kiiskinen T., Broberg M. et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res; 2021: 8 (1): e000845. https://doi.org/10.1136/bmjresp-2020-000845.</mixed-citation><mixed-citation xml:lang="en">Strausz S., Kiiskinen T., Broberg M. et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res; 2021: 8 (1): e000845. https://doi.org/10.1136/bmjresp-2020-000845.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
